Genprex Announces Safety Review Committee Approves Dose Escalation in Acclaim-1 Phase 1/2 Trial of REQORSA™ in Combination with Tagrisso® in Non-Small Cell Lung Cancer

/PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies...

Related Keywords

Texas ,United States ,Astrazeneca Tagrisso ,Mark Berger ,Genprex Inc ,Merck Co Keytruda ,Linkedin ,Drug Administration ,Exchange Commission ,Astrazeneca ,Facebook ,Safety Review Committee ,Recommends Advancing ,Increased Dose ,Second Cohort ,Fast Track Designation ,Immunogene Therapy ,Chief Medical Officer ,Nanoparticle Delivery System ,Private Securities Litigation Reform Act ,Annual Report ,Genprex ,Nc ,